Recent analyses of NHS England data reveal a concerning trend: cancer patients in the UK are facing excessive delays in receiving treatment, with many waiting over 104 days. This situation arises as the majority of NHS trusts fall short of meeting essential waiting time targets, raising alarms about the quality of care available to those battling cancer.
Alarming Wait Times for Patients
The NHS has long established that at least 85% of cancer patients should begin treatment within 62 days of being referred. However, this target has not been met since 2014, leading to growing frustration among patients and healthcare advocates alike. The latest statistics disclose that only three out of 119 acute trusts achieved or exceeded this 85% threshold last year. Disturbingly, some of the lowest-performing trusts managed to treat only half of their patients within the required timeframe.
The three trusts that successfully met the 85% benchmark in 2025 were Calderdale and Huddersfield (89.2%), Homerton Healthcare (85.8%), and Maidstone & Tunbridge Wells (85.7%). In stark contrast, trusts such as Mid & South Essex, Sheffield Teaching Hospitals, and Hull University Teaching Hospitals lagged significantly, treating just 45.4%, 50.1%, and 53.1% of patients within the target period, respectively.
Incremental Improvements, Yet Significant Gaps Remain
Across England, 69.1% of cancer patients—approximately 239,038 out of 345,847—began treatment within the 62-day window last year. This figure represents a slight improvement from 67.7% in 2024. Notably, while 65 of the 119 trusts reported an increase in the number of patients treated on time, 54 saw a decline, underscoring the inconsistency in service delivery.
In a few trusts, the situation is even more dire, with reports indicating that at least one in seven patients who commenced treatment in December 2025 had endured waits exceeding 104 days. The University Hospitals of Leicester recorded that 13.7% of patients faced such delays, while Hull University Teaching Hospitals reported an alarming 16.5% waiting beyond the acceptable timeframe.
Government Targets and the Road Ahead
In light of these challenges, the UK Government has set an interim target for 75% of patients to begin treatment within 62 days by March 2026. However, experts warn that achieving this goal will require significant investments in NHS staffing and equipment.
Michelle Mitchell, Chief Executive of Cancer Research UK, emphasised the urgency of the situation, stating, “Every cancer patient deserves access to timely, high-quality care.” She pointed out that while NHS staff are making commendable efforts to manage increasing pressures, the number of individuals facing unacceptable delays remains unacceptably high.
Further complicating the landscape, the NHS often struggles to maintain progress on cancer treatment timelines. Bea Taylor, a fellow at the Nuffield Trust, noted that the UK continues to lag behind other countries regarding cancer outcomes, and a lack of investment in key diagnostic equipment is hampering progress.
A Call for Action and Commitment
Healthcare leaders from various trusts have expressed their commitment to addressing these issues. For instance, Kirsten Major, Chief Executive of Sheffield Teaching Hospitals, acknowledged the decline in performance and outlined that improving cancer waiting times is a top priority. She reported that steps are already being taken to enhance capacity through additional clinics and diagnostic services.
Similarly, NHS representatives from trusts like Hull University Teaching Hospitals and Mid & South Essex have shared ongoing improvement initiatives aimed at accelerating diagnosis and treatment. These include investing in new technologies, expanding outpatient clinics, and optimising surgical scheduling to enhance patient care.
Why it Matters
The ongoing delays in cancer treatment are more than just numbers; they represent real individuals enduring prolonged uncertainty and anxiety during a profoundly challenging time. As the NHS grapples with these systemic issues, it is crucial for policymakers to prioritise investment in healthcare resources and infrastructure. Ensuring timely access to cancer treatment is not only a matter of meeting targets but fundamentally about saving lives and providing patients with the quality of care they deserve in their most vulnerable moments.
